ArticleCureus2025
A Rare Case of Osmotic Demyelination Syndrome in Advanced Pancreatic Adenocarcinoma Without Hyponatremia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osmotic demyelination syndrome (ODS) is a rare neurological disease involving myelin loss in the central nervous system and is traditionally linked with abrupt correction of hyponatremia. In the absence of hyponatremia, ODS can occur if there are other risk factors such as malignancy, malnutrition, and metabolic disturbances. We describe a 52-year-old male with advanced pancreatic adenocarcinoma and liver metastases who presented with confusion, falls, bilateral leg oedema, hyperglycemia and hypokalemia. Initial imaging was negative for intracranial pathology but positive for pancreatic and hepatic malignancy. The patient's condition deteriorated despite intravenous insulin and potassium, and a brain MRI was positive for central pontine ODS without evidence of metastatic disease. Sodium levels were within normal limits on hospitalisation. A multi-disciplinary team deemed the malignancy inoperable, and the patient was transferred to palliative care and died three weeks post-discharge. This case illustrates the multifactorial aetiology of ODS in cancer patients, with a contribution from malignancy-related nutrient deficiencies, hypokalemia, and hyperglycemia despite normal sodium. Current literature identifies oligodendrocyte susceptibility to energy deficiency in cancer as a predisposition to ODS. This report highlights the significance of heightened awareness of ODS in malignancy, even in the absence of hyponatremia, and calls for further research into its pathophysiological basis as well as management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.